SAN DIEGO, March 10, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary Kannaway® has launched a new cannabidiol (CBD) product, its Hemp + Calm Oral Applicator, in Europe. This product is the Company’s first product available in Europe that is made using its Blue Label Real Scientific Hemp Oil™ (RSHO™).
“Europe has proven to be our largest market since we launched across the continent in 2018,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “As the European CBD market continues to grow exponentially, we intend to continue innovating and launching new products that fit the needs of European consumers.”
Each Kannaway® Hemp + Calm Oral Applicator contains 2,000 mg of CBD from broad-spectrum hemp oil. The CBD used in the product is derived from non-GMO hemp, scientifically extracted using a solvent-free CO2 process, and quality-certified through the Company’s Triple Lab Testing® process to deliver the potential natural benefits of hemp CBD.
According to the Brightfield Group, the CBD market in Europe is expected to grow over 400 percent by 2023. Kannaway® is the first direct selling company to legally offer hemp-based CBD wellness products to the entire European market.
Information on Kannaway® in Europe or on how to become a European Kannaway® Brand Ambassador can be found at https://kannaway.com/.
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Investor Relations Contact:
P. (858) 283-4016